英文原著
1. Kudo A , Machii N, Ono T, Saito H, Oshiro Y, Takahashi T, Oshiro K, Taneda Y, Higa M, Nakachi K, Yagi S, Masuzaki H, Sata M, Shimabukuro M. Effect of dapagliflozin on 24-h glycaemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicentre, randomised, open-label, parallel-group study. BMJ Open Diabetes Res Care in press Pubmed
2. Shiroma K, Tanabe H, Takiguchi Y, Yamaguchi M, Sato M, Saito H, Tanaka K, Masuzaki H, Kazama JJ, Shimabukuro M. A nutritional assessment tool, GNRI, predicts sarcopenia and its components in type 2 diabetes mellitus: A Japanese cross-sectional study. Front Nutr 2023;10:1087471. Pubmed
2. Shiroma K, Tanabe H, Takiguchi Y, Yamaguchi M, Sato M, Saito H, Tanaka K, Masuzaki H, Kazama JJ, Shimabukuro M. A nutritional assessment tool, GNRI, predicts sarcopenia and its components in type 2 diabetes mellitus: A Japanese cross-sectional study. Front Nutr 2023;10:1087471. Pubmed
3. Takahashi A et al. Impact of lifestyle and psychosocial factors on the incidence of hepatobiliary enzyme abnormalities after the Great East Japan Earthquake: Seven-year follow-up of the Fukushima Health Management Survey. Disaster Med Public Health Prep in press Pubmed
英文総説
1. Shimabukuro M. Nonsteroidal mineralocorticoid receptor antagonists and protection against cardiovascular disease in patients with diabetes mellitus. J Atheroscler Thromb in press Pubmed
2. Shimabukuro M. MAFLD and ASCVD: plasma heparin cofactor II activity as an anti-liver fibrosis biomarker. J Atheroscler Thromb in press Pubmed
2. Shimabukuro M. MAFLD and ASCVD: plasma heparin cofactor II activity as an anti-liver fibrosis biomarker. J Atheroscler Thromb in press Pubmed
